Q1 EPS Estimate for Gain Therapeutics Increased by Analyst

Gain Therapeutics, Inc. (NASDAQ:GANX) – Stock analysts at HC Wainwright raised their Q1 2026 EPS estimates for shares of Gain Therapeutics in a report issued on Monday, March 30th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($0.13) for the quarter, up from their previous estimate of ($0.15). HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Gain Therapeutics’ current full-year earnings is ($1.00) per share. HC Wainwright also issued estimates for Gain Therapeutics’ Q2 2026 earnings at ($0.13) EPS, Q4 2026 earnings at ($0.11) EPS, FY2026 earnings at ($0.50) EPS, Q1 2027 earnings at ($0.12) EPS, Q2 2027 earnings at ($0.12) EPS, Q3 2027 earnings at ($0.13) EPS, Q4 2027 earnings at ($0.11) EPS and FY2027 earnings at ($0.47) EPS.

A number of other equities research analysts have also issued reports on GANX. Roth Mkm reaffirmed a “buy” rating and issued a $10.00 target price on shares of Gain Therapeutics in a research note on Friday, December 19th. Weiss Ratings reissued a “sell (e+)” rating on shares of Gain Therapeutics in a report on Monday, December 29th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $8.50.

Gain Therapeutics Trading Up 7.8%

Shares of GANX opened at $1.94 on Wednesday. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.63 and a quick ratio of 6.63. Gain Therapeutics has a 1-year low of $1.41 and a 1-year high of $4.34. The stock has a market cap of $81.95 million, a price-to-earnings ratio of -3.18 and a beta of -0.03. The firm has a 50 day simple moving average of $2.13 and a 200-day simple moving average of $2.37.

Gain Therapeutics (NASDAQ:GANX) last announced its quarterly earnings results on Thursday, March 26th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.03.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Marshall Wace LLP lifted its stake in shares of Gain Therapeutics by 849.3% during the 4th quarter. Marshall Wace LLP now owns 1,662,293 shares of the company’s stock worth $5,353,000 after purchasing an additional 1,487,186 shares during the period. Potomac Capital Management Inc. purchased a new stake in shares of Gain Therapeutics in the fourth quarter valued at $3,252,000. Jane Street Group LLC grew its position in shares of Gain Therapeutics by 234.5% in the fourth quarter. Jane Street Group LLC now owns 242,328 shares of the company’s stock valued at $780,000 after purchasing an additional 169,878 shares during the period. LPL Financial LLC acquired a new position in Gain Therapeutics in the fourth quarter valued at $343,000. Finally, State Street Corp increased its stake in Gain Therapeutics by 72.9% in the fourth quarter. State Street Corp now owns 157,537 shares of the company’s stock valued at $507,000 after purchasing an additional 66,400 shares during the last quarter. 11.97% of the stock is currently owned by institutional investors and hedge funds.

About Gain Therapeutics

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.